The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare.
Carl is Professor of EBM & Director of CEBM at the University of Oxford. He is also a GP and tweets @carlheneghan. He has an active interest in discovering the truth behind health research findings
EBM for Under 18’s is supporting teachers through the creation of resources that emphasise opportunities to teach critical thinking using
Read More
Carl Heneghan
The Mesh Story The above timeline sets out the major landmarks for transvaginal surgical mesh since its first approval in
Introductory Workshop in Evidence-Based Practice Bedford Hall, Dublin Castle, Dame St, Dublin 12th – 14th MARCH 2019 Our Objectives: To
Carl Heneghan and David Nunan
This one day workshop gives an introduction to EBM for journal editors…
EBM for Under 18s is a project that supports introducing Evidence-Based Medicine (EBM) as part of the wider science activities in schools.
Inside Britain’s Fertility Business BBC Panorama, 28th Nov 2016 Exclusive new research by the Centre for Evidence-Based Medicine shows a worrying
This talk was given at the introduction to Evidence-based Practice course at Rewley House on October 10th. The talk
In humanitarian disasters you need people with acute trauma care skills to find and rescue those who can be
This talk was given at the 2016 Preventing Overdiagnosis Conference in Barcelona, Spain As the closing keynote this talk focuses on Carl
Evidence-Based Medicine for clinical years: Sep 13th 2016 Professor Carl Heneghan Download the pdf of the talk Go to the
This talk was given by Professor Carl Heneghan at Continuing Education Open Day in Sep 2016 Download the talk: (Assessing
In April 2014, the Cochrane review on neuraminidase inhibitors was published alongside BMJ summary reviews. The review found that while
Poor quality evidence, lack of affordability and uninformed patients suggest an awful lot of research doesn’t actually matter. However, for
The first two articles in this series pointed out we need better and more affordable evidence. Yet, even if affordable
